Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets tough blood cancers in early trial

NCT ID NCT05428969

Ongoing Disease control Sponsor: Faron Pharmaceuticals Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taking part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia hematopoietic and lymphoid system neoplasm myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA MYELODYSPLASTIC SYNDROMES RELAPSED / REFRACTORY AML

Contacts and locations

Locations

  • City of Hope National Medical Center

    Duarte, California, 91010, United States

  • Helsinki University Hospital

    Helsinki, 00029, Finland

  • Kuopio University Hospital

    Kuopio, 70210, Finland

  • Oulu University Hospital

    Oulu, 90029, Finland

  • Royal Cornwall Hospitals NHS Trust

    Truro, United Kingdom

  • Tampere University Hospital

    Tampere, 33520, Finland

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.